Gastroenterology

Gastroenterology

Volume 120, Issue 5, April 2001, Pages 1183-1192
Gastroenterology

Liver, Pancreas, and Biliary Tract
Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities,☆☆,

https://doi.org/10.1053/gast.2001.23256Get rights and content

Abstract

Background & Aims: The pathogenesis of nonalcoholic steatohepatitis (NASH) is unknown. We tested the hypothesis that NASH is associated with 2 defects: (1) peripheral insulin resistance, which increases lipolysis, delivery of free fatty acids (FFA) to the liver, and hepatic fatty acid β oxidation, thereby creating oxidative stress; and (2) an abnormality within the hepatocytes that might render them more susceptible to injury from oxidative stress. Methods: The hypothesis was tested by evaluation of (1) insulin resistance by a 2-step hyperinsulinemic (10 and 40 mU · m−2 · min−1) euglycemic clamp; (2) insulin effects on lipolysis by enrichment of [U-13C]glycerol; (3) frequency and severity of structural defects in hepatocyte mitochondria in vivo; (4) fatty acid β oxidation from serum [β-OH butyrate], release of water-soluble radioactivity from 3H-palmitate by cultured fibroblasts and urinary dicarboxylic acid excretion; and (5) hepatic lipid peroxidation by immunohistochemical staining for 3-nitrotyrosine (3-NT). Subjects with NASH (n = 6–10 for different studies) were compared with those with fatty liver (n = 6) or normal controls (n = 6). Results: NASH and fatty liver were both associated with insulin resistance, with mean glucose infusion rates (normal/fatty liver/NASH) of step 1, 4.5/1.6/0.9; step 2, 9.5/7.7/4.5 (P < 0.03 for both steps). Although baseline rates of glycerol appearance were higher in those with NASH than in those with fatty liver (means, 14.6 vs. 21.6 μmol · kg−1 · min−1; P < 0.05), neither group significantly suppressed glycerol appearance at insulin infusion rates of 10 mU · m−2 · min−1. NASH was associated with loss of mitochondrial cristae and paracrystalline inclusions in 9 of 10 subjects, compared with 0 of 6 subjects with fatty liver. However, no evidence of a generalized defect in fatty acid β oxidation was noted in any group. Also, mean [β-OH butyrate] was highest in those with NASH (means, 90 vs. 110 vs. 160 μmol/L; P < 0.04). Increased staining for 3-NT was present in fatty liver, and even greater staining was seen in NASH. Conclusions: These data indicate that peripheral insulin resistance, increased fatty acid β oxidation, and hepatic oxidative stress are present in both fatty liver and NASH, but NASH alone is associated with mitochondrial structural defects.

GASTROENTEROLOGY 2001;120:1183-1192

Section snippets

Subjects studied

The studies were performed in patients with NASH who did not have severe morbid obesity (body mass index [BMI] > 40), gastric bypass, diabetes, or cirrhosis (test group) and compared with 2 other groups: (1) age-, gender-, and weight-matched controls with fatty liver alone that was not associated with alcohol, medications, morbid obesity, or gastric bypass surgery; and (2) gender-matched normal controls. NASH was diagnosed using a combination of commonly used histologic and clinical criteria2

Results

A total of 6 subjects each with NASH and fatty liver were studied (Table 1) and compared with 6 lean normal controls.The normal controls were significantly younger (P < 0.01, Kruskal–Wallis ANOVA) than those with NASH or fatty liver alone. The BMI and body fat content of normal subjects were less (P < 0.02, Kruskal–Wallis ANOVA) than those with NASH or fatty liver. Although the BMI of subjects with fatty liver was similar to that of subjects with NASH, the body fat content of those with NASH

Discussion

Obesity and diabetes are the 2 best-known risk factors for the development of both fatty liver and NASH.1 Both risk factors are associated with insulin resistance14 and are considered components of syndrome X.13, 14, 32 The present study confirms that insulin resistance is uniformly present in subjects with fatty liver or NASH, even in the absence of diabetes, and extends the spectrum of the syndrome to include both of these conditions.

According to our original hypothesis, it was predicted that

References (47)

  • DR Nelson

    Metazoan cytochrome P450 evolution

    Comp Biochem Physiol C Pharmacol Toxicol Endocrinol

    (1998)
  • J Ludwig et al.

    Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

    Mayo Clin Proc

    (1980)
  • EE Powell et al.

    The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

    Hepatology

    (1990)
  • J Ludwig et al.

    Review: nonalcoholic steatohepatitis

    J Gastroenterol Hepatol

    (1997)
  • EM Brunt et al.

    Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions

    Am J Gastroenterol

    (2000)
  • AL Baker

    Nonalcoholic steatonecrosis: a unique histopathologic lesion of the liver with multiple causes

    Surv Dig Dis

    (1985)
  • P Rozental et al.

    Liver morphology and function tests in obesity and during total starvation

    Am J Dig Dis

    (1967)
  • S Itoh et al.

    Five patients with nonalcoholic diabetic cirrhosis

    Acta Hepatogastroenterol Stuttg

    (1979)
  • M Abdelmalek et al.

    Two cases from the spectrum of nonalcoholic steatohepatitis

    J Clin Gastroenterol

    (1995)
  • SG Sheth et al.

    Nonalcoholic steatohepatitis

    Ann Intern Med

    (1997)
  • G. Reaven

    Syndrome X: 10 years after

    Drugs

    (1999)
  • RA DeFronzo et al.

    Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease

    Diabetes Care

    (1991)
  • T Kawasaki et al.

    The relationship between fatty liver and hyperinsulinemia in obese Japanese children

    J Pediatr Gastroenterol Nutr

    (1997)
  • Cited by (1868)

    • Roles of immune dysregulation in MASLD

      2024, Biomedicine and Pharmacotherapy
    View all citing articles on Scopus

    Supported in part by National Instututes of Health grants DK 02755 (to A.J.S.) and DK 43013 (to J.N.C.) and by grant MO1 RR 00065-38 to the General Clinical Research Center at the Virginia Commonwealth University-Medical College of Virginia.

    ☆☆

    Address requests for reprints to: Arun J. Sanyal, M.D., MCV Box 980711, Medical College of Virginia, Richmond, Virginia 23298-0711. e-mail: [email protected]; fax: (804) 828-2037.

    Previously published in abstract form (Gastroenterology 1999;116:1271A) and presented at the annual meeting of the American Association for Study of Liver Disease in Orlando, Florida, 1999.

    View full text